Clinical Trials Directory

Trials / Completed

CompletedNCT01600170

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

Statin Modulation of Monocyte/Macrophage Activation for HAND Treatment

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
11 (actual)
Sponsor
University of Pennsylvania · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

HIV associated neurological disorders (HAND), are a major problem even in ART treated people. HAND results from chronic inflammation which is largely attributed to expansion and activation of monocytes. These activated monocytes, some of which also carry virus to the brain, invade the CNS and release cytokines / chemokines resulting in further recruitment of monocytes, as well as release viral proteins which injure neurons and cause activation of other brain cells. Persistent monocyte/macrophage activation is thus a potential critical target for adjunctive therapy to treat or prevent HAND. The investigators therefore propose to study the effects of a statin drug (Atorvastatin), which has anti-inflammatory functions, on the monocyte activation status in ART treated HIV+ individuals. The investigators objectives are based on the hypothesis that Atorvastatin treatment will reduce the inflammatory and activated phenotype and function of monocytes which have been linked to HIV associated neuropathogenesis and occur in HIV infected subjects despite ART. In this study the investigators propose to 1\) define the effect of Atorvastatin on monocyte activation in HIV infected / ART treated subjects in a double blind, placebo controlled crossover study

Conditions

Interventions

TypeNameDescription
DRUGAtorvastatin (generic Lipitor)Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
DRUGplaceboA substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.

Timeline

Start date
2013-01-01
Primary completion
2017-10-01
Completion
2017-10-01
First posted
2012-05-16
Last updated
2020-11-23
Results posted
2020-11-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01600170. Inclusion in this directory is not an endorsement.